Review
Open access
Sep 2026
Flavonoids for MASLD: Hepatic Lipid Targets, Biopharmaceutic Barriers, and Formulation Strategies
The evidence supports viewing flavonoids as formulation-dependent investigational candidates rather than established MASLD therapies, as their therapeutic development is constrained by poor aqueous solubility, extensive intestinal and first-pass metabolism, variable activity of circulating metabolites, and limited info...
Shuo Yan, Hui Yang, Ying-Rui Wang et al.
· Pharmaceuticals · 0 citations